Ergoteles LLC Kura Oncology, Inc. Transaction History

Ergoteles LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$11.23 - $16.9 $307,746 - $463,127	27,404 New	27,404 $340,000
Q2 2022 Aug 12, 2022	SELL	$10.71 - $18.33 $344,422 - $589,474	-32,159 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$11.78 - $16.98 $47,579 - $68,582	-4,039 Reduced 11.16%	32,159 $517,000
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $263,023 - $421,224	21,524 Added 146.68%	36,198 $507,000
Q3 2021 Nov 15, 2021	SELL	$15.42 - $21.72 $48,202 - $67,896	-3,126 Reduced 17.56%	14,674 $275,000
Q2 2021 Aug 12, 2021	BUY	$20.85 - $29.88 $62,550 - $89,640	3,000 Added 20.27%	17,800 $371,000
Q1 2021 May 12, 2021	BUY	$24.75 - $39.14 $366,300 - $579,272	14,800 New	14,800 $418,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.